Qiagen has reported that the company and Bristol-Myers Squibb will explore the use of NGS to develop gene expression profiles as predictive or prognostic tools for use with several BMS immuno-oncology therapies. The companies also plan to enter into a further agreement to develop diagnostic products using the jointly developed profiles to expand the use of NGS technology with other BMS immuno-oncology therapies.
“Greater precision in the treatment of cancer may enable faster decision making to identify which patient populations are most likely to derive benefit from our immuno-oncology agents.”
–Fouad Namouni, Bristol-Myers Squibb
This development is an example of the trend towards companion diagnostics, in which the use of predictive biomarkers identify individually-based therapies.
Read the announcement here.
Get more genomic news at GenomeWeb